Navigation Links
Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP
Date:11/5/2007

tion to the FDA seeking a new indication for first line angina and a significant reduction in cautionary language.

Ranexa is currently indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

Study Design

MERLIN TIMI-36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) was a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in 6,560 patients (3,279 received ranolazine, 3,281 received placebo) with non-ST elevation ACS treated with standard therapy.

Within 48 hours of the onset of angina due to ACS, eligible hospitalized patients were enrolled in the study and randomized to receive intravenous Ranexa or placebo, followed by long-term outpatient treatment with Ranexa extended-release tablets or placebo. All patients also received standard therapy during both hospital-based and outpatient treatment. The doses of Ranexa extended-release tablets used in MERLIN TIMI-36 have been studied in previous Phase 3 clinical trials.

Participants in the MERLIN TIMI-36 study received current standard therapy, with approximately 96 percent of patients on aspirin, approximately 89 percent on beta blockers and approximately 82 percent on statins. Approximately 59 percent of study participants received coronary angiography during their initial hospitalization.

Previously published data from the MERLIN TIMI-36 study has shown that Ranexa was safe in this population of patients with coronary artery disease, which included nearly 1,100 patients with prior heart failure.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecula
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
2. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
3. Study shows adverse drug events reported to the FDA have significantly increased
4. Rehabilitation significantly underused after heart attack and bypass surgery
5. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
6. National Domestic Violence Hotline Unveils 10-Year Blueprint to Significantly Reduce Domestic Violence in America
7. New Study Shows Arthritis Significantly Limits Millions of Americans Ability to Work
8. World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths
9. Psychiatrists, parents significantly differ in ADHD, psychiatric comorbidities perceptions
10. Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C
11. Abbotts Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , ... July 30, 2015 , ... Quintessa Medical Spa ... is a nonsurgical treatment designed specifically for the elimination of excess tissue ... the first locations in the state of Wisconsin to offer this innovative treatment. , ...
(Date:7/30/2015)... , ... July 30, 2015 , ... Gummy smile ... lip lowering, gum contouring and surgery, as well as the patented gum depigmentation treatmet. ... has made him popular with many patients from around the world. , “Like treatment ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... entity on behalf of the New Jersey Department of Health, has received a ... Technology, an agency of the U.S. Department of Health and Human Services (HHS). ...
(Date:7/30/2015)... ... ... New research finds some distinct differences in the way mesothelioma behaves in younger ... website. , Researchers with the National Institutes of Health, the FDA, and the ... between 1990 and 2010. Two percent of these cases (207) occurred in people younger ...
(Date:7/30/2015)... ... , ... Bird B Gone, the leader in bird control products for commercial, ... pest birds from the AC units and ventilation systems on hospital roofs. Bird droppings ... West Nile virus. When these droppings dry, the fine powder can be carried into ...
Breaking Medicine News(10 mins):Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2
... ... for Healthcare Professionals. , ... Bristol, TN (PRWEB) February 3, 2010 -- King Pharmaceuticals, Inc. ... tools, and essential resources to healthcare professionals and others, helping them provide optimal, ...
... ... American Heart Association’s “Go Red for Women” event in Denver, Colorado. , ... Independence, OH (PRWeb) February 3, ... Red for Women” event in Denver, Colorado. The “Speak Up To Save Lives” ...
... , ... to help healthcare professionals with health literacy solutions for the 90 million literacy challenged ... ... for Healthcare Advancement (IHA), a not-for-profit healthcare organization and a national leader in health ...
... ... In this day and age of specialization and compartmentalization, liberal arts and ... study. For individuals who desire a well-rounded, more classical education, a ... subjects can range from communications and journalism to general arts and the ...
... WASHINGTON , Feb. 2 Sanford Wittels ... announced today that AtriCure, Inc., a medical device company specializing in ... Department of Justice (DOJ) and the Office of the Inspector General ... million plus interest over a five-year period. Sanford Wittels ...
... better, study found , TUESDAY, Feb. 2 (HealthDay News) -- ... will be able to kick the habit and reduces the ... found. , The study included 568 adults who smoked 10 ... year. The smokers who used nicotine patches for the entire ...
Cached Medicine News:Health News:King Launches Painbalance: Educational Initiative to Help Reduce the Burden of Pain 2Health News:King Launches Painbalance: Educational Initiative to Help Reduce the Burden of Pain 3Health News:King Launches Painbalance: Educational Initiative to Help Reduce the Burden of Pain 4Health News:Life Line Screening Supports the American Heart Association's 'Go Red for Women' Event in Denver, Colorado 2Health News:Institute for Healthcare Advancement's Ninth Annual Health Literacy Conference Set for May 6-7, 2010 in Irvine, Calif. 2Health News:Institute for Healthcare Advancement's Ninth Annual Health Literacy Conference Set for May 6-7, 2010 in Irvine, Calif. 3Health News:OnlineEducation.com Announces Expansion of Liberal Arts & Humanities to its Accredited Online Degree Programs 2Health News:OnlineEducation.com Announces Expansion of Liberal Arts & Humanities to its Accredited Online Degree Programs 3Health News:OnlineEducation.com Announces Expansion of Liberal Arts & Humanities to its Accredited Online Degree Programs 4Health News:Relator's Attorneys Comment on AtriCure/DOJ Settlement 2Health News:Relator's Attorneys Comment on AtriCure/DOJ Settlement 3Health News:Using Nicotine Patch Longer Boosts Efforts to Quit 2
(Date:7/30/2015)... July 30, 2015 Tissue ... the regenerative medical devices company, announces that it ... wound care market as Tissue Regenix Wound Care ... Medicare administrator, First Coast Service Options Inc. ("First ... , Puerto Rico and ...
(Date:7/29/2015)... , July 30, ... Guidance   ... including Core Earnings and ... Highlights of Q1 results  ... Underlying core earnings and underlying core EPS were flat, year-to-year , ...
(Date:7/29/2015)... -- Insulet Corporation (NASDAQ: PODD ), the leader ... Insulin Management System, today announced preliminary revenue results ... Company also announced that it will postpone the full ... call from Thursday, July 30, as originally scheduled.   ... , Preliminary second quarter revenue results: ...
Breaking Medicine Technology:Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 2Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 3Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 2Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 3Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 4Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 5Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5
... LONDON, March 19, 2007-AstraZeneca today announced that ... results from the ARISE (Aggressive Reduction of ... which studied,AGI-1067, an investigational anti-atherosclerotic agent with,antioxidant ... disease (CAD). ,The ARISE trial did not ...
... /PRNewswire-FirstCall/ --,Nuvelo, Inc. today announced that clinical data ... MACE)/TIMI 32 Phase,2 trial looking at recombinant nematode ... coronary syndromes,(NSTE-ACS) will be presented in a V-poster ... Session taking place in New,Orleans, LA, March 24-27, ...
Cached Medicine Technology:Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet,Primary Endpoint 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 3
... new Oculus Easygraph is a corneal ... tools you need for refractive surgery, ... therapy contact lens fitting in a ... 4" package. All you need to ...
The only ergonomic work station of its kind with an optional built-in keratograph and flat-screen. The Concepta is a modern workstation for the examination and refraction of patients....
The natural look of 3 in 1 technology in virtually any prescription....
Dot matrix pattern for light eyed patients....
Medicine Products: